Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to -$92000.0.

  • Angiodynamics' Cash from Financing Activities rose 9180.77% to -$92000.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $1.4 million, marking a year-over-year increase of 12404.85%. This contributed to the annual value of -$255000.0 for FY2025, which is 9960.31% up from last year.
  • Angiodynamics' Cash from Financing Activities amounted to -$92000.0 in Q4 2025, which was up 9180.77% from $143000.0 recorded in Q3 2025.
  • Over the past 5 years, Angiodynamics' Cash from Financing Activities peaked at $24.4 million during Q3 2022, and registered a low of -$59.6 million during Q3 2023.
  • Its 5-year average for Cash from Financing Activities is -$2.6 million, with a median of $103000.0 in 2022.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 952000.0% in 2021, then crashed by 44174.76% in 2023.
  • Over the past 5 years, Angiodynamics' Cash from Financing Activities (Quarter) stood at $942000.0 in 2021, then crashed by 89.07% to $103000.0 in 2022, then crashed by 441.75% to -$352000.0 in 2023, then plummeted by 219.03% to -$1.1 million in 2024, then surged by 91.81% to -$92000.0 in 2025.
  • Its Cash from Financing Activities was -$92000.0 in Q4 2025, compared to $143000.0 in Q3 2025 and -$5.8 million in Q2 2025.